NEW YORK (GenomeWeb News) – Epigenomics today announced it has submitted the third of four modules to US regulators for possible approval of its Epi proColon blood-based colorectal cancer screening test.

The German molecular diagnostics company said it expects to submit the fourth and final module to the US Food and Drug Administration in the second half of this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.